$4.57
3.16% yesterday
Nasdaq, Sep 27, 10:17 pm CET
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Geron Corporation Stock price

$4.57
-0.09 1.93% 1M
+1.26 38.07% 6M
+2.46 116.59% YTD
+2.40 110.60% 1Y
+3.12 215.17% 3Y
+3.22 238.52% 5Y
+2.41 111.57% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.14 3.16%
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Key metrics

Market capitalization $2.67b
Enterprise Value $2.39b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,747.13
P/S ratio (TTM) P/S ratio 1,949.19
P/B ratio (TTM) P/B ratio 8.68
Revenue growth (TTM) Revenue growth 205.11%
Revenue (TTM) Revenue $1.37m
EBIT (operating result TTM) EBIT $-227.37m
Free Cash Flow (TTM) Free Cash Flow $-208.59m
Cash position $363.86m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 45.33
EV/Sales forward 40.63
Short interest 11.20%
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Geron Corporation forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Geron Corporation forecast:

Buy
100%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1.37 1.37
204% 204%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 104 104
82% 82%
7,577%
- Research and Development Expense 122 122
6% 6%
8,941%
-226 -226
31% 31%
-16,508%
- Depreciation and Amortization 1.21 1.21
23% 23%
88%
EBIT (Operating Income) EBIT -227 -227
31% 31%
-16,596%
Net Profit -220 -220
28% 28%
-16,026%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Positive
Seeking Alpha
4 days ago
Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise in treating MDS and MF, with significant clinical trial results and manageable adverse events. Geron's financials are strong with a $2.8bn market cap and cash runway until 2026, positioning it well ...
Neutral
Business Wire
8 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on September 18,...
Neutral
Business Wire
18 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and opera...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO John Scarlett
Employees 141
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today